Information meeting 3 April 2018 2017 ANNUAL RESULTS 1 3 April - PowerPoint PPT Presentation

2017 Annual Results Information meeting 3 April 2018 2017 ANNUAL RESULTS 1 3 April 2018

Table of contents 1. Introduction Thierry Chapusot 2. 2017 financial results Jean-Yves Samson 3. Business developments & Outlook Dominique Pautrat 4. Conclusion Thierry Chapusot 2017 ANNUAL RESULTS 2 3 April 2018

In France and Europe Comparable trends throughout Europe • Population aging :  growth in healthcare demand,  without an increase in the number of doctors. • Ensuring continuity in care across the patient pathway:  managing the patient care process is a major healthcare priority.  to ensure this coordination and traceability the information flow must be optimised between the different healthcare stakeholders, for both the non-hospital and hospital segments • New technologies are providing highly efficient solutions to address these issues: with the growth in patient-related data, market players must offer innovative solutions for organising and processing collected data . • And while technology is indispensable to effectively integrate the human dimension, the pharmacist in Europe is becoming THE coordinator of health. Their proximity to patients means they are more accessible and more often consulted. For that reason, they are destined to assume an increasingly 2017 ANNUAL RESULTS 3 3 April 2018 active role in the patient care management process.

Our global vision of healthcare Pharmagest Group has been anticipating these trends for more than 5 years • Offering a solution for the shortage of doctors: actively engaged in research and development for telemedicine solutions. • The priority of continuity in care for the patient pathway: AXIGATE's acquisition contributes to continuity of care and improved information flows across both non-hospital and hospital segments. Pharmagest is the only player offering a solution for structuring healthcare coordination across non-hospital and hospital segments to be rolled out in 2019. • Organisational innovation: the Group has been working for several years on building its patient-centred technology infrastructure and services, a dedicated global ecosystem where the pharmacist can legitimately be considered to fulfil a role as primary care provider and coordinator. Pharmagest is the first company to propose a global "patient- centred" ecosystem through a healthcare platform to date unique in 2017 ANNUAL RESULTS 4 3 April 2018 Europe.

Our global vision of healthcare A broad strategic vision for Europe All of Pharmagest Group's acquisitions are focused on this ambition to become a key contributor to the transformation of the healthcare in France and Europe: • SABCO • SAILENDRA • CAREMEDS / MULTIMEDS • AXIGATE • MACROSOFT 2017 ANNUAL RESULTS 5 3 April 2018

2017 Annual Results Financial results 2017 2017 ANNUAL RESULTS 6 3 April 2018

2017 Annual Results 2017 financial highlights Revenue ( € m) Net profit ( € m) + 14.35 % + 13 % 24,3 146,8 21,5 128,4 113,5 19 2015 2016 2017 2015 2016 2017 Basic earnings per share (in € ) Net profit attributable to equity holders of the Parent + 12.7 % ( € m) 1,55 + 12.5 % 23,1 1,37 20,6 1,25 18,8 2015 2016 2017 2015 2016 2017 2017 ANNUAL RESULTS 7 3 April 2018 7

2017 Annual Results 2017 revenue ( € m) 2017 2016 Change Q1 35.42 30.46 + 16.30 % Q2 36.60 33.07 + 10.69 % Q3 35.24 30.00 + 8.46 % Q4 42.24 34.86 + 21.19 % Annual Revenue 146.81 128.38 + 14.35 % 2017 ANNUAL RESULTS 8 3 April 2018

2017 Annual Results Financial results Profit and loss statement ( € m) 2017 2016 Change REVENUE 146.81 128.38 + 14.35 % OPERATING PROFIT 34.52 31.39 + 10 % NET PROFIT 24.25 21.46 + 13 % NET PROFIT ATTRIBUTABLE 23.13 20.57 + 12.5 % TO THE PARENT BASIC EARNINGS 1.55 1.37 + 12.7 % PER SHARE (en € ) 2017 ANNUAL RESULTS 9 3 April 2018

2017 Annual Results 2017 financial highlights by Division Operating Operating In € thousands Revenue profit margin (%) Pharmacy Europe 101,953 23,999 23.54% Health and Social 14,863 6,578 44.26% Care Facilities Other e-Health 29,990 3,942 13.14% & Fintech Total 146,806 34,519 23.51% 2017 ANNUAL RESULTS 10 3 April 2018

2017 Annual Results Financial highlights by Division (IFRS 15) Operating Operating In € thousands margin (%) Revenue profit in IFRS 15 Pharmacy Europe 101,731 23,879 23.47% Health and Social 14,863 6,578 44.26% Care Facilities Other e-Health 12,986 3,847 29.63% & Fintech Total 129,580 34,304 26.47% 2017 ANNUAL RESULTS 11 3 April 2018

2017 Annual Results Financial results Balance sheet ( € m) Dec. 2017 Dec. 2016 Dec. 2017 Dec. 2016 NON-CURRENT ASSETS 84.37 66.75 SHAREHOLDERS' EQUITY 115.83 103.65 R&D 13.60 10.07 Attributable to the Parent 113.25 101.96 Goodwill 38.82 30.45 Non-current financial assets 19.08 15.04 NON-CURRENT LIABILITIES 21.96 8.18 Other non-current assets 12.87 11.19 Long-term debt 14.20 3.44 Other non-current liabilities 7.75 4.74 CURRENT ASSETS 90.16 83.94 Trade receivables 20.25 CURRENT LIABILITIES 22.94 36.74 38.87 Other current assets 11.51 8.53 Short-term debt 2.68 6.96 Cash & cash equivalents 27.58 27.57 Trade payables 9.56 8.20 Available-for-sale securities* 28.13 27.59 Other current liabilities 24.50 23.71 TOTAL 150.70 TOTAL 174.53 150.70 174.53 * and other financial assets 2017 ANNUAL RESULTS 12 3 April 2018

2017 Annual Results Cash flow highlights ( € m) Net cash at 31/12/2016 (**) 63.72 Cash flow + 28.57 Change in WCR -1.09 Operating investments (*) - 7.94 Financial investments - 10.54 Dividends - 10.04 Borrowings + 9.64 Other financing activities + 0.36 Net cash at 31/12/2017 (**) 72.68 (*) Of which € 5,864,000 for R&D (**) Of which available-for-sale securities ( € 28.13m) + non-current 2017 ANNUAL RESULTS 13 3 April 2018 financial assets ( € 18.46 m) = € 46.59m

2017 Annual Results Capital expenditures for R&D In € thousands 2017 2016 Pharmacy Europe 2,868 1,993 Health and Social Care 752 231 Facilities e-Health Solutions 1,662 1,008 & Fintech 582 596 Total 5,864 3,828 2017 ANNUAL RESULTS 14 3 April 2018

2017 Annual Results Ratios 2015 2016 2017 € 21.1m € 23.96m € 28.57m Cash Flow GEARING (*) -58.48 % -57.34 % -49.45% ROE 21% 20.2% 20.4% (*) net debt including available-for-sale securities and other financial assets 2017 ANNUAL RESULTS 15 3 April 2018

2017 Annual Results Share price trends over the year 03.04.2017 => 26.03.2018 - Source - BOURSORAMA +58.47% at 26/03/2018 : at 03/04/2017: share price of € 33.76 share price of € 53.50 2017 ANNUAL RESULTS 16 3 April 2018

Solutions for Pharmacy Division Europe - 2017 Pharmacy France 2017 revenue: +3.9% to € 101.95m 2017 operating profit: € 23.999m Representing 69.5% of total Group revenue + 1.13% / 2016 • • Good growth for equipment sales The slower rise in profit for this and market share gains. Division reflects the reorganisation and restructuring • Growth of recurrent revenue. costs linked to the Group's • international development. Success of our comprehensive pharmacy management package • The profit margin registered (LMO). further gains in line with growth in • sales. The "Patient-Centred" strategy has started to deliver results. • An excellent business performance in Belgium, with two major contracts with the MULTIPHARMA and COOP networks. 2017 ANNUAL RESULTS 17 3 April 2018

Health and Social Care Facilities Solutions Division - 2017 Retirement Homes 2017 revenue: +44.5% to € 14.86m 2017 operating profit: € 6.578m Representing 10.1% of total Group revenue + 64% / 2016 • • The acquisition of AXIGATE: a Operating Profit boosted by French Hospital Information Systems acquisitions, AXIGATE (07/2017) and DICSIT (03/2016). leader. • • On this basis, Pharmagest Group is These entities market exclusively high added-value services. able to propose an original and exclusive solution covering both the • On a pro forma basis, Operating health and social care facilities and Profit was up 14.64%. non-hospital care pathway. 2017 ANNUAL RESULTS 18 3 April 2018